Yvonne Nanciu
I used to write about my skills, now I would rather tell you about my passions: I am passionate about Patient Safety, and helping people become their best selves. Great communicator in several languages, with a love of arts and food from all around the world. My greatest assets are being empathetic, good humored and not being afraid of changes. Oh yes, and I do bring over 15 years of pharmacovigilance and leadership experience to the table, in various local and global functions. I am currently working at Bayer, as PV Country Head in Germany and being the Deputy EU QPPV.
Yvonne Nanciu
PV Country Head Germany and Deputy EU QPPV Bayer
Thursday 6 June
Patient Involvement for Better PV Knowledge - Driving Patient Centricity Through Your PV Project
Patients need to play a crucial role in the decision-making regarding their own disease treatment and therapy options. However, their knowledge of Pharmacovigilance (PV) aspects is still quite limited despite the industry´s effort to make the science of Pharmacovigilance and the importance of adverse event reporting more popular - and palatable. What I am hoping through this presentation is to share from our experience, and have an open discussion about what can we do differently/better to reach our patients, putting their safety first.
- The importance of patient-centricity as the main driver of PV activities
- Aspects to consider when setting up a Patient Support Program
- What can we do with limited budget to reach our patients
- Is there a specific PV time to shine during the year? Highlights from last year´s Patient Safety Day and Med Safety Week
- Open discussion and exchange of ideas
Yvonne Nanciu
PVCH Germany, Deputy EU QPPV
Bayer
Thursday 6 June
Panel Discussion: Navigating the Complexities of Drug Safety And the Digital Age
- Discuss the role of real-world data in pharmacovigilance and its impact on drug safety assessments
- Explore opportunities for leveraging digital health data for proactive adverse event monitoring and patient-reported outcomes
- Outsourcing landscape – Partnership model working – Technology and services
- Examine ethical dilemmas related to pharmacovigilance, including issues of patient privacy, informed consent, and the balance between public health surveillance and individual rights
- Examine how AI and ML technologies are transforming pharmacovigilance processes, including adverse event detection, signal detection, and risk assessment
